Alzheimer's disease of experimental mice is curable now!

Molecular biologists have successfully created and tested the first reverse transcriptase therapy for Alzheimer's disease by use of recombinant mouse proteins, which protects mice from disease. The study was published in the Proceedings of the National Academy of Sciences (PNAS).

"Our results show that gene therapy can be used to treat Alzheimer's disease, although it is too early to talk about this. Therefore, we must overcome a large number of obstacles. In addition to direct injection of brain, we can't induce this gene therapy through other methods," said Magdalena Sastre at the Imperial College in London, UK.

In the last two years, biologists have gained a better understanding of the causes of Alzheimer's disease and the definition of the disease. For example, recently scientists have found that Alzheimer's disease may be transmitted; β-amyloid plaques may be an important part of the innate immune system; and some therapies that are expected to treat the disease.

One approach - forcing the PPARGC1A protein associated with cell self-purification systems and cellular metabolic work to actively counteract beta-amyloid plaques. Sastre and colleagues believe that this process can be achieved by gene therapy (embedding other copies of the gene in hippocampal cells, storage centers, and the cerebral cortex). To test this idea, the scientists grew a population of mice with Alzheimer's disease and introduced a special retrovirus that contained other copies of the PPARGC1A protein in their brains. Another group of uninfected rodents was the control group.

Four months later, scientists compared the state change of the two groups of rats. It was found that the presence of a copy of the PPARGC1A protein had a very positive effect on rodent status, significantly reducing the amount of beta-amyloid protein entanglement in the rat nerve cells and preventing the negative effects produced by the development of Alzheimer's disease.

According to scientists, these mice have good memory, and they complete the task of finding a maze outlet and the ability to deal with other cognitive problems as much as not suffering from Alzheimer's disease in healthy rodents. The fact that rodents are healed proves that almost no cell survives in the hippocampus and cortex. When Alzheimer's disease enters the final stage, neurons usually die in large numbers.

Scientists hope their research will serve as the basis for the development of retroviral vaccines that can be adapted to humans without the need to inject potentially lethal drugs directly into the brain. According to scientists, this gene therapy can not only adapt to the existing Alzheimer's disease, but also can be used as a special vaccine to prevent disease development. Flarebio offers good-quality recombinant proteins such as recombinant ITGB2 at good prices.